Market Research Logo

BioTime Inc (BTX) - Product Pipeline Analysis, 2018 Update

Summary

BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company BioTime Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


BioTime Inc Company Overview
BioTime Inc Company Snapshot 5
BioTime Inc Pipeline Products and Ongoing Clinical Trials Overview
BioTime Inc – Pipeline Analysis Overview 8
Business Description 8
BioTime Inc - Key Facts 8
BioTime Inc - Major Products and Services 9
BioTime Inc Pipeline Products by Development Stage 10
BioTime Inc Ongoing Clinical Trials by Trial Status 12
BioTime Inc Pipeline Products Overview 14
BioTime Films 14
BioTime Films Product Overview 14
BioTime Sponges 15
BioTime Sponges Product Overview 15
Drug Delivery Device - Ankle Fracture 16
Drug Delivery Device - Ankle Fracture Product Overview 16
HyStem - BDNF 17
HyStem - BDNF Product Overview 17
HyStem-Spine 18
HyStem-Spine Product Overview 18
HyStem-Tendon 19
HyStem-Tendon Product Overview 19
PanC-Dx - Colon Cancer 20
PanC-Dx - Colon Cancer Product Overview 20
PanC-Dx - Prostate Cancer 21
PanC-Dx - Prostate Cancer Product Overview 21
ReGlyde 22
ReGlyde Product Overview 22
ReGlyde Drug Delivery Device  - Osteoarthritis 23
ReGlyde Drug Delivery Device  - Osteoarthritis Product Overview 23
Renevia 24
Renevia Product Overview 24
Renevia Clinical Trial 25
BioTime Inc - Key Competitors 26
BioTime Inc - Key Employees 27
BioTime Inc - Key Employee Biographies 28
BioTime Inc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 30
Recent Developments 31
BioTime Inc, Recent Developments 31
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 31
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 31
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 32
Mar 13, 2018: BioTime Submits CE Mark Application for European Approval of Renevia 34
Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 35
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 35
Jan 29, 2018: Renevia Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference 36
Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 36
Jan 22, 2018: Hologic's Cynosure Division Launches TempSure Envi 37
Jan 22, 2018: BioTime Announces Clinical and Corporate Milestone Targets of Renevia for 2018 37
Appendix 39
Methodology 39
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
BioTime Inc Pipeline Products and Ongoing Clinical Trials Overview 5
BioTime Inc Pipeline Products by Equipment Type 6
BioTime Inc Pipeline Products by Indication 7
BioTime Inc Ongoing Clinical Trials by Trial Status 7
BioTime Inc, Key Facts 8
BioTime Inc, Major Products and Services 9
BioTime Inc Number of Pipeline Products by Development Stage 10
BioTime Inc Pipeline Products Summary by Development Stage 11
BioTime Inc Ongoing Clinical Trials by Trial Status 12
BioTime Inc Ongoing Clinical Trials Summary 13
BioTime Films - Product Status 14
BioTime Films - Product Description 14
BioTime Sponges - Product Status 15
BioTime Sponges - Product Description 15
Drug Delivery Device - Ankle Fracture - Product Status 16
Drug Delivery Device - Ankle Fracture - Product Description 16
HyStem - BDNF - Product Status 17
HyStem - BDNF - Product Description 17
HyStem-Spine - Product Status 18
HyStem-Spine - Product Description 18
HyStem-Tendon - Product Status 19
HyStem-Tendon - Product Description 19
PanC-Dx - Colon Cancer - Product Status 20
PanC-Dx - Colon Cancer - Product Description 20
PanC-Dx - Prostate Cancer - Product Status 21
PanC-Dx - Prostate Cancer - Product Description 21
ReGlyde - Product Status 22
ReGlyde - Product Description 22
ReGlyde Drug Delivery Device  - Osteoarthritis - Product Status 23
ReGlyde Drug Delivery Device  - Osteoarthritis - Product Description 23
Renevia - Product Status 24
Renevia - Product Description 24
Renevia - A Randomized, Evaluator-blinded, Delayed-treatment-controlled Study of the Effectiveness and Safety of Renevia, A Resorbable Matrix for the Delivery of Autologous Adipose Derived Cells to treat Subcutaneous Facial Lipoatrophy Defects Arising from HIV 25
BioTime Inc, Key Employees 27
BioTime Inc, Key Employee Biographies 28
BioTime Inc, Subsidiaries 29
BioTime Inc, Joint Venture 30
Glossary 41
List of Figures
BioTime Inc Pipeline Products by Equipment Type 6
BioTime Inc Pipeline Products by Development Stage 10
BioTime Inc Ongoing Clinical Trials by Trial Status 12

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report